CPIC statistics

Tool stats & trends

Looking to identify usage trends or leading experts?

CPIC specifications


Unique identifier OMICS_17654
Alternative name Clinical Pharmacogenetics Implementation Consortium
Restrictions to use None
Community driven No
Data access File download, Browse
User data submission Not allowed
Maintained Yes

Publications for Clinical Pharmacogenetics Implementation Consortium

CPIC citations


The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database

Clin Pharmacol Ther
PMCID: 5836850
PMID: 29134625
DOI: 10.1002/cpt.910

[…] , including panels, array platforms, and Next‐Generation Sequencing. Examples include the Pharmacogenomic Clinical Annotation Tool (PharmCAT), which takes genomic data to make haplotype calls and get CPIC annotations (https://www.pharmgkb.org/page/pharmcat); Astrolabe, a tool developed to assign CYP2D6 genotype from Whole Genome Sequence data (currently expanded to CYPs 2C9 and 19); or tools that […]


CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic

PMCID: 5538219
PMID: 28808507
DOI: 10.1080/20009666.2017.1347475

[…] h clopidogrel for underlying coronary artery disease, of which 21 (36.2%) were normal metabolizers, 19 (32.7%) were slow metabolizers and 18 (31.0%) were fast metabolizers ().According to the current CPIC guidelines, the following changes were made: Switching to prasugrel (antiplatelet medication not effected by CYP2C19) in PM genotype which improves clinical outcome;Discontinuing or lowering clop […]


Pharmacogenetic testing through the direct to consumer genetic testing company 23andMe

BMC Med Genomics
PMCID: 5477417
PMID: 28629370
DOI: 10.1186/s12920-017-0283-0

[…] ng PubMed and EMBASE assess the pharmacogenetic test fully. The variants reported by 23andMe were matched to the FDA Table of Pharmacogenomic Biomarkers in Drug Labelling []. Additional evidence from CPIC guidelines, [] PharmGKB, [] and Dutch Pharmacogenetics Working Group (DPWG) [] was reviewed to determine current clinical practice. SNP allele frequencies and linkage disequilbrium (LD) between S […]


Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network

BMC Med Genomics
PMCID: 5441047
PMID: 28532511
DOI: 10.1186/s12920-017-0273-2

[…] for Family Health, to identify potentially eligible patients and return results to providers through best practice alerts []. Mount Sinai has selected variants based on published guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) and other organizations and has prioritized those for which testing is permitted by New York State Clinical Laboratory Improvement Amendments […]


A comprehensive phylogenetic analysis of copper transporting P1B ATPases from bacteria of the Rhizobiales order uncovers multiplicity, diversity and novel taxonomic subtypes

PMCID: 5552934
PMID: 28217917
DOI: 10.1002/mbo3.452

[…] monella typhimurium (SilP), belonging to this subtype, 25 rhizobial homologs contain a His‐rich extension at the N‐terminal MBD characteristic of subgroup P1B‐3. Like the P1B‐1 subgroup, they present CPIC as the invariant CXXC motif at N‐terminal MBD as well as a CPC motif at TM 6, instead of the invariant CPH motif distinctive of P1B‐3‐Cu+‐ATPases (Table  and Table Cu‐ATPase subtypes). Following […]


Big Data Analytics for Genomic Medicine

Int J Mol Sci
PMCID: 5343946
PMID: 28212287
DOI: 10.3390/ijms18020412

[…] netic variants generated by NGS. More importantly, the methods should comply with the U.S. Food and Drug Administration (FDA) guideline [] and the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline []. […]


Looking to check out a full list of citations?

CPIC institution(s)
Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA; Department of Genetics, Stanford University, Palo Alto, CA, USA; Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology, University Hospital, Tuebingen, Germany; Department of Pharmacology, University of Extremadura, Cáceres, Spain; Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Laboratory for Informatics Development, NIH Clinical Center, Bethesda, MD, USA; Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; School of Chinese Medicine, China Medical University, Taichung, Taiwan; Department of Medicine, Vanderbilt University, Nashville, TN, USA; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medical Sciences, Clinical Pharmacology, Uppsala University, Uppsala, Sweden; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands; Department of Pharmacology, Vanderbilt University, Nashville, TN, USA; Genomic Medicine Institute, Geisinger Health System, Danville, PN, USA; Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, CO, USA; Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, CO, USA
CPIC funding source(s)
This work was funded by the National Institutes of Health/National Institute of General Medical Science (NIH/NIGMS) (PAAR4Kids (UO1 GM92666), PharmGKB (R24 GM61374)), the Brain & Behavior Research Foundation Award, CIHR Michael Smith New Investigator Salary Prize for Research in Schizophrenia, the Ontario Mental Health Foundation New Investigator Fellowship, an Early Researcher Award by the Ministry of Research and Innovation of Ontario, the Swedish Research Council (Medicine 523-2008-5568 and 521-2011-2440), the Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Madrid, Spain (PI12/00241 and RETICS RD12/0013/0002), the NIH (T32 GM007569/GM/NIGMS), the NIH NIGMS (K23GM104401), the NIH/NIGMS U19 GM61388 and U19 HL065962.

CPIC reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review CPIC